EMPA, a selective inhibitor of SGLT2, has been reported to exert cardioprotective effects in several cardiovascular diseases, including diabetic cardiomyopathy (DCM) (Li et al., 2019), myocardial infarction (Andreadou et al., 2017), cardiorenal syndrome (Yang et al., 2019), and doxorubicin-induced heart failure (Oh et al., 2019). The gene discussed is SLC5A2; the disease is myocardial infarction.